<DOC>
	<DOC>NCT00402168</DOC>
	<brief_summary>The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied</brief_summary>
	<brief_title>A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Men and women age 18 and older 636 months after kidney transplant receiving cyclosporine or tacrolimus calculated GFR ≥35 and ≤75mL/min/1.73 m² subjects must have completed 1 year in the IM103010ST and remained on study treatment (Long Term Extension) Key Significant infection acute rejection within 3 months prior graft loss due to rejection pregnancy positive crossmatch</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>